NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Adrenomed AG

Adrenomed AG

Private
HennigsdorfHealthcare & Life Scienceshttps://adrenomed.com/

Last Round

Series E

Nov 30, 2020

Total Funding Raised

$53.77M

Company Overview

Adrenomed AG is a biopharmaceutical company that develops a first-in-class antibody to rescue vascular integrity in critically ill patients.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Clinical Trials, Precision Medicine, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

septic shock treatmentEnibarcimabfirst-in-class antibodymonoclonal antibodyvascular integritybiomarker-guided therapyprecision medicineAdrenomedullinendothelial barrier functionsepsis therapyclinical-stage biopharmacritical care medicinedrug developmentFDA Fast TrackAdrecizumab

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Adrenomed AG Comparables

Compare Adrenomed AG with similar companies based on industry and business-model similarity.

Adrenomed AG comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Inotrem
88%
4TEEN4 Pharmaceuticals GmbH
87%
Matisse Pharmaceuticals
83%

Adrenomed AG Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series ENov 30, 2020
Series DNov 26, 2018

Key People

Founding team and executive leadership

Jens Schneider-Mergener

Chief Executive Officer

Executive Team

David Germonpré

Chief Financial Officer

Executive Team

Adrenomed AG Investors

Notable investors and investment history

Adrenomed AG investors
InvestorRounds
Investitionsbank des Landes BrandenburgSeries D
HBM Healthcare InvestmentsDebt, Series E, Series D
Wellington PartnersDebt, Series E, Series D

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jan 5, 2026

    Monthly visitors grew 81% MoM.

  • May 4, 2025

    Monthly visitors grew 75% MoM.

Adrenomed AG Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Adrenomed AG Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Adrenomed AG's valuation, stock price, and market status.

Firmographic Details

HeadquartersHennigsdorf
Employee Range16
Year Founded2009
Last FundingNov 30, 2020

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.